Core Viewpoint - Wanfu Biotech (300482) is focusing on strategic collaborations and technological advancements in the field of AI and gene sequencing to enhance its product offerings and market presence. Group 1: Strategic Collaborations - The company signed a strategic cooperation agreement with Tencent Health in May 2025, aiming to explore AI applications in disease detection, clinical decision support, and family health management [2] - The collaboration with Beiden Medical is seen as a key step to tap into the vast market potential in grassroots healthcare, focusing on optimizing products to meet the core needs of "accurate, fast, simple, and affordable" [4][5] Group 2: Technological Advancements - The company is exploring the integration of AI technology with gene sequencing to improve data analysis and interpretation efficiency, although specific product plans were not disclosed [2][3] - There are plans to develop more user-friendly devices suitable for grassroots healthcare settings, addressing the need for quick identification in rural health centers [4] Group 3: Market Outlook and Growth Targets - The global market for gene sequencing is projected to reach $20.2 billion by 2032, prompting the company to set mid- to long-term growth targets for its gene sequencing business [3] - The company is actively monitoring industry trends and is expected to provide updates on its core products' sales and revenue contributions in future reports [5] Group 4: Financial Insights - On February 5, 2026, Wanfu Biotech's stock closed at 20.65 yuan, down 0.91%, with a trading volume of 68,000 shares and a turnover of 140 million yuan [1] - On the same day, there was a net outflow of 3.77 million yuan from main funds, indicating a slight withdrawal of institutional investment [6]